Fatigue, depression and progression in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 815-822

  Koch, Marcus W ^a   Uyttenboogaart, M ^a   van Harten, A ^a   Heerings, M ^a   de Keyser, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Depression; Disability; Fatigue; Progression

Indexed keywords

ADULT; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT MONITORING; PROGNOSIS; RATING SCALE; RISK ASSESSMENT; SURVIVAL; SYMPTOMATOLOGY;

ADULT; COHORT STUDIES; DEPRESSION; DISABILITY EVALUATION; DISEASE PROGRESSION; FATIGUE; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK FACTORS;

EID: 48349143130     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508088937     Document Type: Article

References (24)

1. Krupp, L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler 2006; 12: 36 7-368.
2. Siegert, RJ, Abernethy, DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76: 469-475.
3. Bjartmar, C, Wujek, JR, Trapp, BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-171.
4. Colosimo, C, Millefiorini, E, Grasso, MG, Vinci, F, Fiorelli, M, Koudriavtseva, T, et al. Fatigu in MS is associated with specific clinical features. Acta Neurol Scand 1995; 92: 353-355.
5. Patten, SB, Lavorato, DH, Metz, LM. Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry 2005; 27: 439-445.
6. Bakshi, R, Czarnecki, D, Shaikh, ZA, Priore, RL, Janardhan, V, Kaliszky, Z, et al. Brain MRI lesions and atrophy are related to depression multiple sclerosis. Neuroreport 2000; 11: 1153-1158.
7. Mohr, DC, Hart, SL, Julian, L, Cox, D, Pelletier, D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004; 328: 731.
8. Mohr, DC, Goodkin, DE, Bacchetti, P, Boudewyn, AC, Huang, L, Marrietta, P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000; 55: 55-61.
9. Poser, CM, Paty, DW, Scheinberg, L, McDonald, WI, Davis, FA, Ebers, GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
10. Kremenchutzky, M, Rice, GP, Baskerville, J, Wingerchuk, DM, Ebers, GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 29: 584-594.
11. Krupp, LB, LaRocca, NG, Muir-Nahsh, J, Steinberg, AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
12. Radloff, LS. The CES-D scale, a self-report depression scale for research in the general population. J Appl Psychol Measurement 1977; 1: 385-401.
13. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis. an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Roxburgh, RH, Seaman, SR, Masterman, T, Hensiek, AE, Sawcer, SJ, Vukusic, S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
15. European Study Group. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
16. Secondary Progressinv Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-1504.
17. Rovaris, M, Confavreux, C, Furlan, R, Kappos, L, Comi, G, Filippi, M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
18. Tellez, N, Rio, J, Tintore, M, Nos, C, Galan, I, Montalban, X. Fatigue in multiple sclerosis persists over time: A longitudinal study. J Neural 2006; 253: 1466-1470.
19. Minden, SL, Frankel, D, Hadden, L, Perlodoffp, J, Srinath, KP, Hoaglin, DC. The Sonya Slifka longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006; 12: 24-38.
20. Sadovnick, AD, Remick, RA, Allen, J, Swartz, Yee, IM, Eisen, K, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-632.
21. Bakshi, R, Shaikh, ZA, Miletich, RS, Czarnecki, D, Dmochowski, J, Henschel, k, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000; 6: 181-185.
22. Heesen, C, Nawrath, L, Reich, C, Bauer, N, Schulz, KH, Gold, SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behavious? J Neurol Neurosurg Psychiatry 2006; 77: 34-39.
23. Tartaglia, MC, Narayanan, S, Francis, SJ, Santos AC, De Stefano, N, Lapierre, Y, et al. The relationship between diffuse axonal damage and fatigue in multipte sclerosis. Arch Neurol 2004; 61: 201-207.
24. Duman, RS, Chamey, DS. Cell atrophy and loss in major depression. Biol Psychiatry 1999; 45: 1083-1084.